ビサコジル（坐剤中）　Bisacogyl (in suppository)

日本薬局方におけるカラム選定条件は，「内標準物質，ビサコジルの順に溶出し，その分離度が 2 **以上あるものを用いる」と定められています．**CAPCELL PAK C_{18} MGII **では，分離度が** 9.9 **と良好な分離が得られました．**

The Japanese Pharmacopoeia requires a column to elute compounds in the order of the internal standard and bisacogyl, with a resolution value of 2 or greater between the two compounds. CAPCELL PAK C_{18} MGII showed a resolution of 9.9.



1



2



1. *p*-**オキシ安息香酸エチル** (I.S.) (1.5 μg/mL)
   Ethyl *p*-hydroxybenzoate (I.S.) (M.W. 166.2)
2. **ビサコジル** (10 μg/mL)
   Bisacogyl (M.W. 361.4)

【HPLC Conditions】

Column	：	CAPCELL PAK C_{18} MGII S5 ; 4.6 mm i.d. x 150 mm
Mobile phase	：	10 mmol/L Citric acid / CH_3CN / CH_3OH = 2 / 1 / 1
Flow rate	：	1.1 mL/min
Temperature	：	R.T.
Detection	：	UV 254 nm
Inj. vol.	：	20 μL
Sample dissolved in	：	0.5 mL of ethyl *p*-hydroxybenzoate solution (30 μg/mL in acetonitrile), 0.5 mL of bisacogyl solution (200 μg/mL in tetrahydrofuran) were mixed together. The solution was diluted to 10 mL in a volumetric flask with the mobile phase. ※ 1 μg/mL = 1 ppm